COMMISSION Washington,
D.C.  20549

Under the Securities
Exchange Act of 1934

Applied DNA Sciences, Inc.
(Name of

Common Stock, $0.001 par value
(Title of Class
of Securities)


NeuStrada Capital, LLC
126 East 56th Street, 25th Floor
New York, NY 10022
(Name, Address and Telephone Number
of Person Authorized to
Receive Notices and

July 12, 2013
(Date of Event which Requires
Filing of this Statement)

If the filing person has previously filed a statement on
Schedule 13G to report the acquisition that is the subject
of this Schedule 13D, and is filing this schedule because
of 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including
all exhibits.  See 240.13d-7 for other parties to whom
copies are to be sent.

*  The remainder of this cover page shall be filled out
for a reporting person?s initial filing on this form with
respect to the subject class of securities, and for any
subsequent amendment containing information which would
alter disclosures provided in a prior cover page.

The information required on the remainder of this cover
page shall not be deemed to be ?filed? for the purpose of
Section 18 of the Securities Exchange Act of 1934 (?Act?)
or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the
Act (however, see the Notes).

1. Name of Reporting Persons. NeuStrada Capital, LLC and
Gerald Catenacci

2. Check the Appropriate Box if a Member of a Group (See

(a)Not applicable

(b)Not Applicable

3. SEC Use Only

4. Source of Funds (See Instructions): PF

5. Check if Disclosure of Legal Proceedings Is Required Pursuant
to Items 2(d) or 2(e)

6. Citizenship or Place of Organization: Delaware

Number of Shares Beneficially by Owned by Each Reporting
Person With:

7. Sole Voting Power:  40, 827,268

8. Shared Voting Power:

9. Sole Dispositive Power: 40, 827,268

10. Shared Dispositive Power:

11.Aggregate Amount Beneficially Owned by Each Reporting Person:

12.Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions)

13.Percent of Class Represented by Amount in Row (11)   5.96

14.Type of Reporting Person (See Instructions)  IA, IN

Item 1. Security and Issuer

The Securities covered by this Schedule D are shares of common
stock, par value $.001 per share (Common Stock) of Applied DNA
Sciences, Inc. (the Company), a Delaware corporation.  The
Company?s principal executive offices are located at 25 Health
Sciences Drive, Suite 215, Stony Brook, New York 11790.

Item 2. Identity and Background.

(a)Name:  NeuStrada Capital, LLC

(b) Residence or business address:
126 East 56th Street,
25th Floor
New York, NY 10022
(c) Not applicable

(d) Not applicable

(e) Not applicable

(a)Name:  Gerald Catenacci

(b) Residence or business address:
52 Carriglea Drive
Riverside, CT 06878

(c) Not applicable

(d) Not applicable

(e) Not applicable

Item 3. Source of Funds
As of July 12, 2013, the Reporting Persons held an aggregate of
40,827,268 shares (the "Shares") of common stock  of the issuer as an
investor in a private placement of the issuer's common stock with his own
personal funds through Neustrada Capital LLC
 as well as through acquisition of the Shares by exercising
his option as director on the Board of Directors.

Item 4. Purpose of Transaction

(a) As of July 12, 2013 Neustada Capital LLC sold 2,562,138 shares
and Gerald Catenacci acquired 586, 453 shares upon the exercising of
an option as director on the Board of Directors on June 11, 2013.
(b) Not applicable
(c) Not applicable
(d) Not applicable
(e) Not applicable
(f) Not applicable
(g) Not applicable
(h) Not applicable
(i) Not applicable
(j) Not applicable

Item 5. Interest in Securities of the Issuer
(a) As of the date of this report, the Reporting Persons beneficially
own,  in the aggregate, 40,827,268 shares of the Company's
Common stock representing 5.96%
of the Company's 684, 484, 654 outstanding common stock shares.

(b) The number of shares as to which there is sole power to vote are

(c) Not applicable
Item 6. Contracts, Arrangements, Understandings, or Relationships
with Respect to Securities of the Issuer:
 In connection with the purchase of securities, the Applied DNA
Sciences, Inc. agreed to use best efforts to nominate Mr. Catenacci
to the Board and elect him as director within 30 days of the closing
of the Private Placement and providing for the nomination and
inclusion of Mr. Catenacci on the slate of nominees for the company's
Board of Directors for election by stockholders at the annual
meetings of stockholders for so long as Neustrada owns at least 2% of
the company's outstanding shares of common stock as stated in the
Compan's 10-k for the fiscal year 2011 (File Number 002-90539).
Item 7. Material to be Filed as Exhibits.

Signature. After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this
statement is true, complete and correct.


Gerald Catenacci, President &
Managing Member of
Neustrada Capital LLC


The original statement shall be signed by each person on whose behalf
the statement is filed or his authorized representative. If the
statement is signed on behalf of a person by his authorized
representative (other than an executive officer or general partner of
the filing person), evidence of the representative's authority to sign
on behalf of such person shall be filed with the statement: Provided,
however, That a power of attorney for this purpose which is already on
file with the Commission may be incorporated by reference. The name and
any title of each person who signs the statement shall be typed or
printed beneath his signature.